Last reviewed · How we verify
blood sample - Bacteraemia group
blood sample - Bacteraemia group is a Biologic drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development.
A blood sample from a Bacteraemia group is typically collected to diagnose and monitor bacterial infections, such as those caused by respiratory infections, bacteremia, or central line infections. The sample is often analyzed using standard laboratory procedures to identify the presence and type of bacteria in the blood.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | blood sample - Bacteraemia group |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood Culture Volume
- Infectious Diseases in Aged Population (NA)
- Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
- The Clinical Impact of Cobas® Eplex Blood Culture Panels for the Diagnosis of Bacteremia and Fungemia (NA)
- Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis
- Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
- Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis
- Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- blood sample - Bacteraemia group CI brief — competitive landscape report
- blood sample - Bacteraemia group updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about blood sample - Bacteraemia group
What is blood sample - Bacteraemia group?
Who makes blood sample - Bacteraemia group?
What development phase is blood sample - Bacteraemia group in?
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing